Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
olaparib pancreatic cancer | 1.06 | 0.8 | 4420 | 9 | 26 |
olaparib | 0.12 | 0.1 | 2435 | 51 | 8 |
pancreatic | 1.66 | 0.4 | 7844 | 5 | 10 |
cancer | 1.57 | 0.8 | 7056 | 70 | 6 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
olaparib pancreatic cancer | 0.8 | 1 | 190 | 65 |
olaparib pancreatic cancer fda | 1.03 | 1 | 7198 | 45 |
olaparib pancreatic cancer nice | 0.86 | 1 | 1404 | 48 |
palb2 pancreatic cancer olaparib | 0.07 | 0.8 | 2276 | 3 |
olaparib pembrolizumab pancreatic cancer | 0.35 | 0.5 | 3293 | 100 |
olaparib maintenance pancreatic cancer | 1.69 | 0.6 | 1553 | 25 |
olaparib and pancreatic cancer | 0.61 | 0.1 | 6376 | 86 |
olaparib fda approval ovarian cancer | 1.8 | 0.8 | 379 | 32 |
olaparib prostate cancer fda | 1.74 | 0.6 | 223 | 57 |
olaparib fda approval prostate cancer | 0.14 | 0.9 | 5040 | 18 |
olaparib breast cancer approval | 1.49 | 0.9 | 1136 | 18 |
olaparib for breast cancer | 2 | 0.6 | 4853 | 62 |
olaparib for ovarian cancer | 0.18 | 0.7 | 4429 | 36 |
cancer research uk olaparib | 1.22 | 0.1 | 5465 | 96 |
adjuvant olaparib breast cancer fda | 0.89 | 0.7 | 4471 | 77 |
olaparib for metastatic breast cancer | 0.74 | 0.8 | 4651 | 38 |
olaparib breast cancer uk | 1.17 | 0.2 | 2447 | 12 |
olaparib fda approval history | 0.48 | 0.1 | 5506 | 97 |
olaparib for prostate cancer | 0.35 | 0.7 | 8996 | 78 |
olaparib prostate cancer approval | 0.38 | 0.5 | 3293 | 34 |
olaparib breast cancer indication | 0.98 | 0.7 | 9019 | 67 |